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Is cancer a disease that can be cured?
An answer based on a new classification of diseases
Peter Richmond1 and Bertrand M. Roehner2
Abstract Is cancer a disease that can be cured or a degenerative disease which
comes predominantly with old age? We give an answer based on a two-dimensional
representation of diseases that uses two parameters to characterize age-dependent
changes in death rates. These parameters are defined in the following way.
In mortality curves (extending from the day after birth to beyond 90 years of age)
there is an age, namely ac ∼ 10 years, which plays a crucial role in the sense that
the mortality decreases in the interval I1 = (a < ac) and increases in the interval
I2 = (a > ac). The respective trends in I1 and I2 are the two parameters used in
our classification of diseases. Within the framework of reliability analysis, I1 and I2
would be referred to as the “burn-in” and “wear-out” phases. This leads to define
three broad groups of diseases with respect to ac. (AS1) Asymmetry with prevalence
of I1; (AS2) Asymmetry with prevalence of I2 and (S) Symmetry, with I1 and I2 both
playing roles of comparable importance. Not surprisingly, among AS1-cases one
finds all diseases due to congenital malformations and chromosomal abnormalities.
In the AS2-class one finds degenerative diseases, e.g. Alzheimer’s disease and other
dementias. Among S-cases one finds most diseases due to external pathogens or to
a wear-out process. Cancer is one of those mixed cases and in our representation it
turns out to be closer to (AS2) than to (AS1).
This representation also provides insight into what we call an overkill effect in old
age. This effect tells us that even a highly effective cancer therapy would have no
influence whatsoever on the extent of human life unless all other diseases are cured
simultaneously.
We conclude that whilst one might develop a cure for many of the known diseases
of old age, new diseases will arise and the quest for the ultimate cure will be never
ending. Death before the age of 120 seems firmly written in our genetic code and the
best we shall be able to do is to help people cope with the inevitability of death as
and when it arises.
2Introduction
In medical statistics the expression “infant mortality” refers to the first year after
birth and during this first year infant death rates (e.g. early, late and post neonatal)
are defined with respect to live births and not with respect to the living population at
the beginning of the respective time intervals. The 0-1 year definition has its origin
in the recording process of postnatal mortality data. However, it is not a logical
definition in the sense that the one-year age interval has no real biological basis. A
more objective definition of “infant mortality” is suggested by reliability analysis.
For technical devices, infant mortality refers to the entire age interval during which
the mortality rate decreases. For humans this corresponds to the period 0-10 years.
It is this definition of infant mortality which will be used throughout this paper.
For technical devices the successive phases correspond to the well-known stages of
the so-called “bathtub” curve.
(1) Decreasing failure rate: “burn-in” stage during which defective items fail and
are eliminated.
(2) Constant failure rate: normal service stage characterized by a small number of
random failures.
(3) Increasing failure rate: “wear-out” stage during which failures become more
frequent.
Fig. 1 suggests that human life comprises similar stages with however the qualifi-
cation that the constant failure phase covers only a short interval from about 8 to 12
years. For that reason it will be omitted in the subsequent discussion.
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Fig. 1a,b Death rate from all causes, USA, 1999-2014. In graph (a) the two x scales are linear whereas the
y-scales are logarithmic. In graph (b) the x scale of (0,10) is logarithmic, whereas the x scale of (10,90) is
linear. The two straight lines mean that for (0,10) the death rate is hyperbolic of the form y ∼ 1/xγ , whereas
for (10,90) it is an exponential function in accordance with Gompertz’s law y ∼ eαt. It can be noted that due to
the huge range of variation of the death rate, using a linear scale for y would produce a completely useless graph
in the sense that for (0, 10) it would be a vertical line whereas for adult deaths it would be a line superimposed
on the x axis. Thus, a y log-scale is not just an option, it is a necessity. Source: CDC “Wonder” database
1999-2014 (http://wonder.cdc.gov/ucd-icd10.html). All data are average annual death rates over the 16-year
long interval 1999-2014.
3The burn-in and wear-out phases are characterized by two symmetrical processes:
elimination of defects in the burn-in phase and accumulation of defects in the wear-
out phase.
At first sight such a characterization may seem too crude to be applied to living
organisms. But two observations will help us realize that it can capture essential
features of living systems.
• Table 1 shows that deaths linked to perinatal problems and congenital malfor-
mations dominate death rates in the first month after birth. In subsequent months the
share of these two causes decreases. Overall, for the first year they represent 70% of
the deaths, 16% in the second year and 6.6% for the 9− 10− age group.
Table 1 Predominant causes of death in the infant phase.
Days after birth 0− 1− 1+ − 7− 7+ − 28− 28+ − 365−
Complications of pregnancy and delivery (P00-96) 79% 65% 55% 7.0%
Congenital malformations and abnormalities (Q00-99) 18% 26% 25% 17%
Total (P00-96 + Q00-99) in percent of “All causes” 97% 91% 80% 24%
Notes: Deaths related to perinatal problems and congenital malformations are completely predominant in the
first month after birth. Here 1− denotes the end of the first day (i.e. 23h after birth) whereas 1+ denotes the
beginning of the second day (i.e. 25h after birth). The code numbers following the causes of death are from the
ICD-10 classification, that is to say the 10th revision of the “International Classification of Diseases”; in most
countries it was introduced between 1995 and 2000.
Source: CDC (Centers for Disease Control): “Wonder” database, 1999-2014.
• Many in both the medical community and population at large seem to overlook
the fact that in old age hiding behind any disease that is more or less curable, there is
another one which probably will be more difficult to treat for the simple reason that
it occurs further along the ‘wear-out’ process. For instance, cancer may be followed
by Alzheimer’s disease or another degenerative disease. Fig. 2 from Courchesne
et al. (2000) shows that the volume of gray matter (i.e. the external layer of the
brain) decreases steadily after the age of 10. It is true that the volume of white
matter decreases more slowly but because good functionality requires a combination
of both white and gray matter1, a loss of capabilities seems inevitable. Moreover, the
inset shows that instead of being an “orderly” shrinkage, it is a wear and tear process
which distorts the shape of the brain. Short of freezing the whole dynamic of aging,
it is difficult to imagine how it can be stopped or reversed. Within such a picture,
the diseases of aging should be seen as recurrent manifestations of the global aging
mechanism.
1One needs only remember that white matter consists of more than 100,000 kilometers of nerve fibers which connect
parts of the gray matter with each other.
4Fig. 2 Decrease of the volume of gray matter. The graph describes quantitatively the shrinkage that
the inset shows qualitatively. The data are for 116 healthy volunteers whose mean age was 21.4 years.
From the data points it is apparent that the sample comprised only few elderly people; thus, there
was nobody between 50 and 65 or over 80. Sources: Adapted from Courchesne et al. (2000) and
http://www.health.harvard.edu/brain-imaging (inset).
Classification of diseases
Before we define the classification, it should be noted that in principle one needs not
only death data but also incidence data. By relying on deaths we actually mix up
two phenomena which should be studied separately, that is (i) The emergence of a
disease and (ii) How well a disease can be treated. Diseases which are 100% curable
will not show up in our data and those which are almost completely curable will
appear in reduced form. Fortunately two facts contribute to make death data relevant
nevertheless.
• For most diseases curability is rather limited for the youngest (< 1 day) and
oldest (> 90 year) age groups. This point is related to the so-called rectangulariza-
tion2 of the death rate curve (see Mesle´ and Vallin 2002 and also Berrut et al. 2016,
p. 403, 412).
• We are not interested in absolute death rate values but only in relative death
levels and the latter are more or less proportional to incidence levels. When a disease
can be completely cured it tends to disappear (e.g. smallpox, cholera or tuberculosis).
Class AS1: diseases in which burn-in predominates
Fig. 3 shows a typical case in which burn-in plays a predominant role.
Some congenital malformations may lead to death in the hours after birth whereas
others may bring about death a long time after birth. As a matter of fact, it is quite
remarkable that even 50 years after birth the cause of death can be traced back to a
congenital malformation.
2In our representation it would rather be a triangularization, see Fig. 1 in which there is no plateau.
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Fig. 3 Death rate due to burn-in. On the left, between birth and 10 years, the death rate is divided by 104
whereas on the right it is multiplied by a much smaller factor, namely only 7. This shows that there is a very
active burn-in process which contrasts with a rather sluggish wear-out process. Source: Same as in Fig. 1
Similar values of the exponent γ would be obtained for cases of the same kind. Thus
infant mortality due to “Chromosomal abnormalities” (Q90-99) has γ = 1.18 and
“Complications of pregnancy and delivery” (P00-96) has γ = 1.59.
Class AS2: diseases in which wear-out predominates
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Fig. 4 Death rate due to wear-out. The first deaths due to Alzheimer’s disease occurred in the 10+ − 15−
age group; thus the green broken line should be seen as symbolically representing the level zero for younger
age groups. Source: Same as in Fig. 1
For the case of Alzheimer’s disease shown in Fig. 4 there is no I1 phase in the sense
that for this disease the first death occurs in the 10+ − 15− age group. A similar
shape is observed for similar diseases. Thus for all dementia the contribution of I1 is
also very small and in the I2 phase the doubling time is 6.8 years.
Intermediate cases
6By “intermediate cases” we mean diseases whose rate decreases substantially in the
infant phase and raises significantly in the aging phase.
Common features of diseases due to pathogens
‘Bacterial diseases’ such as the one shown in Fig. 5 are typically of this kind.
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Fig. 5 A case in which there is both burn-in and wear-out. Based on the ranges of the two graphs one may
say that the wear-out process is more considerable than the burn-in process. Source: Same as in Fig. 1
This time, in contrast with Fig. 4, the decline in the infant phase cannot be interpreted
as being due to the existence of pre-natal defects. How then should one interpret such
a graph? A natural interpretation is to say that the decline is due to a strengthening
of the immune system. If correct, this interpretation would lead us to say that there
is a weakening of the immune system starting right away after the age of 10.
Incidentally, we point out here that the peak which occurs between the age of one
month and one year is not a statistical fluctuation for it is found in many countries
and various time periods. We might speculate that it arises in a similar manner to that
observed for fish as they leave the yolk sac and finally forage independently. Thus
here perhaps the peak is related to the fact that between 6 and 12 months, babies shift
from the anti-bodies given by the mother to their own immune system.
This interpretation of the dynamics of the immune system can be tested by examining
other cases in which one would also expect the immune system to play a role. For
instance, in table 2 we examine the case of viral infections,
Difference in adult profiles between bacterial and viral diseases
For viral diseases the increase in the adult phase is much slower than for bacterial
diseases. In addition, as shown in Table 2, the secondary peak is weaker and occurs
earlier.
Distribution of diseases in the (γ, α) plane
The values of the parameters γ, α estimated previously for various diseases can now
7Table 2 Similarities and differences between diseases due to bacteria or viruses.
Disease Position of Exponent of Doubling time of
secondary peak infant decline adult phase
[year] [year]
Bacterial diseases (A00-09+A30-49) 0.53 0.31 ± 0.29 7.6 ± 0.16
Influenza and pneumonia (J09-18) 0.53 0.31 ± 0.24 7.3 ± 0.70
Viral infections (A80-B34) 0.05 0.52 ± 0.21 15.4± 10.5
Notes: It should be noted that the class J09-18 is dominated by bacterial pneumonia (separate data for viral
versus bacterial pneumonia are shown in Fig. 6a). Although it follows broadly the same pattern, the viral case
differs from the bacterial case in two respects (i) the secondary peak occurs earlier (ii) the mortality rate levels
off after the age of 50 instead of increasing steadily as in Fig. 5. These features remain unexplained so far.
Source: CDC (Centers for Diseases Control): “Wonder” database, 1999-2014.
be used to position each disease in the γ, α plane (Fig. 6).
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Fig. 6 Location of diseases in the (γ, α) plane. γ is the power of the hyperbolic fall µb ∼ 1/tγ of the infant
phase while α is the exponent of the exponential increase in the adult phase: µ ∼ eαt. Along the γ axis are
all diseases related to congenital defects including those resulting from preterm birth. Along the α axis are all
degenerative diseases. In between the remaining diseases may be closer to the first or second group denoting a
stronger congenital or degenerative component respectively.
What is the status of cancer?
we now discuss the status of cancer in the present framework.
There is a long standing debate about the status of cancer. Is it a disease that is
8susceptible of being cured (like tuberculosis, say) or is it a degenerative disease (like
Alzheimer’s disease, say)? Can our framework give us some clues?
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Fig. 7 Cancer. Based on the respective ranges of variation of the infant and adult death rates one may say that
the wear-out process is more considerable than the burn-in process. Source: Same as in Fig. 1
For heart diseases the wear-out explanation seems fairly natural. Nobody would
claim that it is possible to cure completely all heart diseases. If one accepts the idea
that the heart is a pump the fact that it is limited to a certain number of beats seems
reasonable3.
Public attitude toward cancer. For cancer the stated objective of many programs is
to find “a cure for cancer”, to “beat cancer” or to “win the war on cancer”4. Thus,
the goal is not just to find a cure for specific forms of cancer but to eradicate cancer
as a major cause of death, just as tuberculosis was eliminated as a major disease.
Status of cancer in the present classification. If cancer is due to a few mechanisms
that may be knocked out, a global remedy may indeed be conceivable. However,
if it is due to a (programmed) weakening of the immune system that hope does not
seem realistic. One faces the same problem for technical devices in the sense that it
is not always obvious whether an increasing failure rate is due to one isolated hidden
defect or to the simultaneous attrition and wear of many components. In the first case
the defect may be eliminated, however in the second case one would need to replace
almost every part of the device.
Fig. 7 shows that in the infant phase cancer looks very similar to the case of bacterial
diseases of Fig. 5 except that there is no secondary peak. In their adult phases
3Cross species comparisons suggest that this number is somewhere between one and two billion beats.
4Just as an illustration, here are three typical sentences.
• “Those who took part in the overnight relay will not rest until a cure for cancer has been found”.
• “Twelve hours of fun, friendship and fundraising to beat cancer”.
• In his speech after signing the ‘National Cancer Act’ of 1971, President Richard Nixon used the expression “the
conquest of cancer”, perhaps in a parallel with the conquest of the Moon.
9the two cases look also very similar both in shape and doubling-time. The case of
bacterial diseases was (tentatively) explained by successive changes in the strength
of the immune system. Surprisingly for a disease such as tuberculosis for which a
treatment is available, its adult phase mortality has a doubling time of about 9.1 years
which is not very different from the doubling time of cancer. The same observation
holds for other bacterial diseases for which antibiotics are supposed to be highly
effective. These features are consistent with a conception in which one assumes that
any therapy, no matter how effective, can only help the immune system but cannot
replace it. Thus, even for a well-treated disease such as tuberculosis, the therapy
barely influences the global death rate at ages beyond 100.
Can the human life span be extended?
Over the past century the life expectancy at birth in developed countries has been
multiplied at least by a factor of two but this was achieved through a fall in infant
and middle-age adult mortality. The ultimate boundary of human life span is still
around 120 years (for more detail in this respect see Richmond et al. 2016). Thus, a
natural question is whether the life span can be extended and what are the conditions
for that.
Keeping the meaning of Gompertz’s law in mind
The difficulty of the challenge can be assessed through the following well-known
(but often forgotten) observation. The number s(t) of radioactive atoms in a sample
decreases as an exponential function of their “age”: s(t) = e−µt. “Beating” an expo-
nential function is already a difficult task; yet, this decrease corresponds to a constant
death rate (1/s)ds/dt = µ whereas Gompertz’s law tells us that in a population of
humans the death rate itself increases exponentially with age µ(t) ∼ eαt. The graphs
presented in the first part of this paper show that the same law also holds at the level
of most individual diseases, albeit with different values of α. Thus, one needs to
“beat a double exponential” which is quite a challenge.
It is true that this fairly standard argument may not sound very compelling because
it is purely mathematical; that is probably why it is often overlooked. In what fol-
lows we present it in a more concrete way which, at the same time, will reveal the
conditions that must be fulfilled to “beat” Gompertz’s law.
First, we introduce a classification of diseases based on how effectively we can treat
them.
Differentiated responses of diseases to therapy
Diseases respond in different ways to our efforts to cure them. This suggests a dis-
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tinction between the following classes.
(1) Diseases which have been eradicated in developed countries, e.g. smallpox,
rabies, cholera5, leprosy. In terms of age-specific death rates these diseases have a
rate close to zero (say below 1 per million) even in old age.
(2) Diseases which are more or less curable, e.g. tuberculosis, pneumonia, hep-
atitis. These diseases are characterized by death rates which are of the order of 1 per
million at age 30 but show a Gompertz-like increase pattern which leads to substan-
tial rates (of the order of 1,000 per million) in old age.
(3) Diseases which are not yet curable, e.g. cerebrovascular accidents, multiple
sclerosis, Alzheimer’s disease. Like those of (2) these diseases have a low rate in
young adults but not at all for the same reason. In (2) it is because an effective
therapy is available whereas in (3) it is because the wear-out process has only just
started.
The diseases in the first two classes are caused by exogenous pathogens whereas
those in class (3) are mostly due to endogenous causes. Cancer and heart diseases
may lie somewhere between (2) and (3) but closer to (3) than to (2).
Although different in terms of therapy, the classes (2) and (3) can be merged together
for the purpose of the forthcoming argument because they both have a substantial rate
in old age.
The “overkill” argument
During the Cold War the expression “overkill capability” referred to the fact that
both the US and the USSR possessed enough nuclear weapons to destroy one another
many times over. Similarly, mortality in old age is ruled by an overkill effect. What
we mean by that expression is that even if a complete cure could be found for 99% of
the diseases with only one disease remaining unchecked, this single disease would
obliterate any sample population, no matter how large, between the ages of 90 and
120. This is due to the fact that the decrease in the number of survivors brought
about by any unchecked disease is exponential which implicates that, unless the
exponent is very small (which would correspond to diseases that are eradicated),
such a decrease will suppress any population within a few years. Just as one atomic
bomb may destroy a whole city, similarly a single unchecked disease may reduce a
whole population to extinction.
Let us illustrate this argument by the case of cancer.
According to Fig. 8d, presently the death rate from cancer at the age of 90 is µ(90) =
1 per 100 and per year. This means that in a sample of 100 people aged 90 the number
5It can be remembered that as late as 1892 an outbreak of cholera claimed 8,600 deaths in Hamburg. Throughout the
19th century there had been similar cholera epidemics in Lon
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of survivors will decrease as:
(1/s)(ds/dt) = µ→ s(t) = s(90) exp[−µ(t− 90)] = 100 exp[−1× (t− 90)]
where t is the age. Thus, one gets:
s(100) = 100 exp(−1× 10) = 0.0045, s(120) ≃ 10−13
Thus, a single unchecked disease is able to suppress the whole population within a
few years.
It can be observed that this is a very conservative calculation in the sense that we as-
sumed that µ(t) keeps its µ(90) value in subsequent years whereas in fact for almost
all diseases µ(t) continues to rise after 90 even though possibly at a slower rate than
before 90.
In contrast, for an eradicated disease the mortality at 90 is of the order of 10−4 per
100. Under such conditions the previous calculation would read:
s(100) = 100 exp(−0.0001× 10) = 99.9, s(120) = 99.7, s(200) = 98
In this case there is a marked extension of the human life span. However, as stressed
above, for this impressive effect to work not a single unchecked disease should re-
main.
The overkill argument can be checked by observation. Over the past century the
eradication of several diseases together with better treatment for a number of others
led to a marked increase in the number of centenarians and supercentenarians (i.e.
older than 110). Yet, the upper bound of the human life span did not change. In 1997
Jeanne Calment died at the age of 122 years and 164 days, a record which remains
unmatched ever since. Moreover she was, so to say, an outlier in the sense that the
second oldest person reached an age of only 119 years and 97 days6. Even if in the
future the record of 122 years is broken most likely it will be surpassed by only a
short margin of less than one year.
How would an effective cancer therapy work in old age?
In 1900 pneumonia and tuberculosis were the leading causes of death in the United
States with annual rates of the order of 2,000 per million7. However, by 1950 death
rates had decreased by a factor of 10 and further reductions occurred in subsequent
6The fact that most of the oldest persons are living in developed countries does not mean that there are no supercente-
narians in developing countries. It is rather due to the fact that in the early 20th century in many developing countries
birth dates were not recorded in a systematic and reliable way. The same reason explains that there are no reliable data
for supercentenarians in the 18th or 19th centuries. Of course, reliable birth data would exist for persons belonging to the
aristocracy but such persons represented but a small proportion of the total population.
7At that time cancer came only in 8th position.
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years. Thus, such therapies can be said as having been really effective. What was
their effect in old ages? In other words how did this therapy affect the shape of the
age-specific curves. Before performing the test we were expecting that, in accor-
dance with Gompertz’s law, the exponential shape would remain unchanged. This
is indeed what we observed albeit with a notable increase in the exponent. In short,
even such highly effective therapies had a much reduced effect on old age mortality.
The same outcome is likely for cancer.
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Fig. 8a,b Pattern of change of death rates over one century in the United States. For tuberculosis and
pneumonia there is a well-defined pattern in the sense that in the adult phase the slope (that is to say the
exponent α) increases as the global mortality decreases. The fact that for Switzerland almost identical curves
are observed suggests that this pattern is shared also by other developed countries. The ICD10 code definition
of tuberculosis and pneumonia are A16-19 and J09-18 respectively. Sources: Linder and Grove (1947, p. 248-
254); Grove and Hetzel (1968, p. 378-469); “Wonder” database of the “Center for Diseases Control” (CDC).
The case of pneumonia suggests that the curves for different years converge toward a
common limit around 110 years. This is another instance of a fixed point mechanism
of the kind that we already studied for global mortality (Richmond et al. 2016).
Adopting this viewpoint, the increase in slope is an obvious consequence since if the
mortality at age 10 falls yet the mortality at age 110 remains stable, the slope of the
straight line joining these two points must increase. For tuberculosis the convergence
to a fixed point (assuming one exists) is much slower. The fact that the curves for
1900 and 1940 are almost flat suggests that the immune system barely changed in
effectiveness over time. This might seem at variance with the suggestion that its
effectiveness declines with age. But note that the death rate in 1900 is already very
high at age around 20 years and comparable with that in old age for adults today.
This then suggests that over time lifestyles, nutrition and medical care have actually
improved the effectiveness of the immune system in young adults today such that the
death rate on the log scale is reduced by 4 orders of magnitude.
Noteworthy observation about the status of Gompertz’s law
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Fig. 8c,d Change of death rates over 60 years in the United States. With their limited death rate reductions,
these diseases belong somewhere between classes 2 and 3 (defined in the text) but closer to the latter than to the
former. The ICD10 codes for intracerebral accident and cancer (malignant neoplasms) are I60-64 and C00-97
respectively. Sources: Vital Statistics of the United States 1950, Volume 3; “Wonder” database of the “Center
for Diseases Control” (CDC).
In order to prevent any confusion we wish to emphasize two points regarding the role
played by Gompertz’s law in the arguments developed in the present paper.
• Our arguments require only what may be called a weak form of the law of
Gompertz, basically that the death rate increases with age but with a slope which is
allowed to fluctuate with age. For instance, whether or not the slope decreases in old
age8 is irrelevant for our reasoning as can clearly be seen in the subsection about the
overkill effect. In fact, this effect will exist (along with the resulting life span wall
around age 120) even if the death rate is assumed to be constant beyond the age of
90. It could even be allowed to decrease slightly (although this is never observed)
without the conclusion of the argument being changed.
• The global “all causes” death rate is an aggregate variable whose properties
depend upon the underlying components. As the underlying diseases do not behave
in the same way their addition will produce a mixed bag which will basically be
controlled by a few predominant components. We have already observed that the
relative importance of diseases has greatly changed over the past century. Therefore
one should not be surprised to see the shape of the global death rate change in the
course of time. Depending on whether tuberculosis or cancer is the predominant
cause of death the shape will not be the same and this will be all the more visible
in old age when the the age groups become smaller and the fluctuations therefore
larger. There may even be transversal differences from country to country due to
differing relative weights of diseases. In other words, from a global perspective, any
discussion about the detailed shape of Gompertz’s function is irrelevant and fairly
8There has been a debate about this point in the past two decades.
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useless.
Conclusion
This paper could have been entitled “Is cancer a disease that can be cured? And,
besides, does it really matter?”. To the first question we could only give an answer
in terms of likelihood. Although we decided against including the second question
into the title, it is in fact this second interrogation that we were able to answer in a
definite way.
We conclude that whilst one might develop a cure for many of the known diseases
of old age, new diseases will arise and the quest for the ultimate cure will be never
ending. Death is inevitable and the best we shall be able to do is to help people cope
with the inevitability of death as and when it arises.
Naturally, our reasoning would be invalidated if major changes to human DNA are
allowed. But that would open uncharted territory which has major ethical implica-
tions for society.
Appendix A: Span of life versus life expectancy
In the previous section we focused on maximum life span rather than on life ex-
pectancy for the simple reason that the 120 year limit is a certainty whereas life
expectancy is a statistical average which gives only a likelihood.
Yet, because life expectancy is a standard demographic indicator it may be of interest
to know how many years a successful cancer therapy would add to it.
We will give two answers.
• The first answer is taken from papers by Jay Olshansky and associates (1990,
2001). Their conclusion can be summarized as follows.
Eliminating all forms of cancer would increase life expectancy at birth by only
three years.
The problem with these papers is that they rely almost purely on statistical projec-
tions. This gives readers precise information but leaves them without real under-
standing. Moreover, these projection techniques are pushed too far sometimes. Just
as an illustration, the paper of 2001 gives projections that extend to 2577; one won-
ders how reliable such long-term projections can be.
• To explain the smallness of the 3 year extension, the key-point is that it is much
more effective to reduce infant and childhood mortality than mid- or old-age mortal-
ity. This is a simple statistical effect that is illustrated in Table A1.
As in developed countries infant mortality is currently at a level of 3 per 1,000 (com-
pared to 150 per 1,000 some 150 years ago) one cannot gain much on this side.
Thus, further reduction must come from therapies for old age diseases. Not only
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Table A1 How life expectancy is affected by a mortality reduction in different age groups
Hypothesis Age group 1 Age group 2 Age group 3 Life expectancy Hi −H0
0− 5 50− 55 80− 85
H0 : Initial death rates 30 30 940 79.20
H1 : Reduced death rate in 1 10 30 960 80.80 1.60
H2 : Reduced death rate in 2 30 10 960 79.80 0.60
Notes: All rates are per 1,000. In order to better show the principle of the calculation the number of age groups
was limited to 3. Under hypothesis H1 short lives of less than 5 years are replaced by lives lasting beyond 80
whereas under hypothesis H2 medium lives in the interval 50-55 are similarly replaced by lives of age group 3.
Thus, there is no surprise in the fact that the increase in life expectancy (i.e. average duration of life) is higher
under H1 than under H2. This effect would be even stronger if group 2 would be an older age group. For
instance, the same calculation with 70-75 as age group 2 gives a difference H1−H2 equal to 1.40 year instead
of 1.00.
This calculation shows that an effective cancer therapy would affect life expectancy at birth much less than the
huge infant and early childhood mortality reduction that occurred during the 20th century.
is this much more difficult to achieve from a medical perspective because these are
degenerative diseases, but in addition, even if successful, it will bring about only
modest extensions of life expectancy.
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